Assessment of safety and immunogenicity of MHC homozygous iPSC-derived CD34+ hematopoietic progenitors in an NHP model.
D'Souza SS, Kumar A, Maufort J, Weinfurter JT, Raymond M, Strelchenko NS, Perrin E, Coonen J, Mejia A, Simmons HA, Torbett BE, Reynolds M, Thomson JA, Slukvin II.
D'Souza SS, et al.
Blood Adv. 2022 Sep 27;6(18):5267-5278. doi: 10.1182/bloodadvances.2022006984.
Blood Adv. 2022.
PMID: 35404997
Free PMC article.